Abstract
Treatment of pancreatic cancer should be a relatively simple clinical problem, all that is needed is to find the features of pancreatic cancer cells that distinguish them from normal cells and target these differences. This is the basis of current therapies including gemcitabine and 5-FU which target DNA synthesis. Unfortunately, cancer cells become resistant to these therapies: By exclusion of drugs from cancer cells; by changes in enzymes metabolising the drugs; or by becoming more resistant to stress and apoptosis. Increasing levels of the drugs is limited by their somatic toxicity so numerous alternative therapies have been proposed. Testing these alternatives in clinical trials will be difficult unless they work with the standard treatments (e.g. gemcitabine). To date most work has concentrated on combining different S-phase targeting agents. Further incremental increase in survival benefit should be possible by targeting resistance to apoptosis, targeting stroma or even targeting multiple pathways in combination with gemcitabine.
Keywords: Pancreatic cancer, Pancreatic ductal adenocarcinoma, chemotherapy, novel therapy, combination therapy, targets, pathways, apoptosis, tumour microenvironment, drug resistance, toxicity
Anti-Cancer Agents in Medicinal Chemistry
Title: Combination Therapy for the Treatment of Pancreatic Cancer
Volume: 11 Issue: 5
Author(s): William Greenhalf and Amy Thomas
Affiliation:
Keywords: Pancreatic cancer, Pancreatic ductal adenocarcinoma, chemotherapy, novel therapy, combination therapy, targets, pathways, apoptosis, tumour microenvironment, drug resistance, toxicity
Abstract: Treatment of pancreatic cancer should be a relatively simple clinical problem, all that is needed is to find the features of pancreatic cancer cells that distinguish them from normal cells and target these differences. This is the basis of current therapies including gemcitabine and 5-FU which target DNA synthesis. Unfortunately, cancer cells become resistant to these therapies: By exclusion of drugs from cancer cells; by changes in enzymes metabolising the drugs; or by becoming more resistant to stress and apoptosis. Increasing levels of the drugs is limited by their somatic toxicity so numerous alternative therapies have been proposed. Testing these alternatives in clinical trials will be difficult unless they work with the standard treatments (e.g. gemcitabine). To date most work has concentrated on combining different S-phase targeting agents. Further incremental increase in survival benefit should be possible by targeting resistance to apoptosis, targeting stroma or even targeting multiple pathways in combination with gemcitabine.
Export Options
About this article
Cite this article as:
Greenhalf William and Thomas Amy, Combination Therapy for the Treatment of Pancreatic Cancer, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677391
DOI https://dx.doi.org/10.2174/187152011795677391 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design The Role of Microbiota and Intestinal Permeability in the Pathophysiology of Autoimmune and Neuroimmune Processes with an Emphasis on Inflammatory Bowel Disease Type 1 Diabetes and Chronic Fatigue Syndrome
Current Pharmaceutical Design Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters The Metabolic Syndrome and the Relevance of Nutrients for its Onset
Recent Patents on Biotechnology The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Melatonin and Hypothalamic-Pituitary-Gonadal Axis
Current Medicinal Chemistry Downregulation of CCKBR Expression Inhibits the Proliferation of Gastric Cancer Cells, Revealing a Potential Target for Immunotoxin Therapy
Current Cancer Drug Targets Hydrogen Sulfide in Inflammation: Friend or Foe?
Inflammation & Allergy - Drug Targets (Discontinued) Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Molecular Basis of Bicarbonate Membrane Transport in the Male Reproductive Tract
Current Medicinal Chemistry PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Review Metabolomics: A New Approach to Drug Delivery in Perinatology
Current Medicinal Chemistry Marine Sesterterpenes: An Overview
Current Organic Chemistry